ArticleMolecular biology2019
Virus-Like Particles as an Instrument of Vaccine Production.
Article in Molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 86 citations in OpenAlex.
- Terminal V5 Tagging of All Four Newcastle Disease Virus Structural Proteins Is Compatible with Particle Formation in Sf9 Cells.International journal of molecular sciences · 2026Article
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- The Use of Virus-like Particles as Immunogens to Treat Infectious Diseases.Current topics in medicinal chemistry · 2026Review
- Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines.Vaccines · 2025Review
- Mucosal immunity and vaccination strategies: current insights and future perspectives.Molecular biomedicine · 2025Review
- Efficacy of Heterologous Vaccination Using Virus-Like Particles and Vaccinia Virus Containing MIC8 and AMA1 Proteins ofVaccines · 2025Article
- Colloidal Crystallization of Virus-Like Particles with Polycations.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Review
- Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.International journal of molecular sciences · 2024Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- When synthetic biology meets medicine.Life medicine · 2024Review
- Virus-Like Particles Based on the Novel Goose Parvovirus (NGPV) VP2 Protein Protect Ducks against NGPV Challenge.Vaccines · 2023Article
- Optimization, characterization, comparison of self-assembly VLP of capsid protein L1 in yeast and reverse vaccinology design against human papillomavirus type 52.Journal, genetic engineering & biotechnology · 2023Article
- Immunogenic Properties and Antigenic Similarity of Virus-like Particles Derived from Human Polyomaviruses.International journal of molecular sciences · 2023Article
- A perspective on SARS-CoV-2 virus-like particles vaccines.International immunopharmacology · 2023Review
- Lessons learned from COVID-19 pandemic: Vaccine platform is a key player.Process biochemistry (Barking, London, England) · 2023Article
- Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022Review
- COVID-19 vaccination challenges: A mini-review.Human vaccines & immunotherapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target antigens on their surface have led to the development of universal platforms which make it possible for virtually any known antigen to be exposed on the particle surface in a highly concentrated form. As a result, the focus of attention has shifted from the approaches to VLP production to the development of a precise interface between the organism's immune system and the peptides inducing a strong immune response to pathogens or the organism's own pathological cells. Immunome-specified methods for vaccine design and the prospects of immunoprophylaxis are discussed. Certain examples of vaccines against viral diseases and cancers are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.